1887

Journal of General Virology header logo

Volume 86, Issue 4

Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C Free

Abstract

The quasispecies nature of hepatitis C virus (HCV) may have important implications concerning resistance to antiviral agents. To determine whether HCV NS5A quasispecies composition and dynamics are related to responsiveness to combined interferon (IFN) and ribavirin therapy, extensive sequence analyses of cloned RT-PCR amplification products of HCV-1b NS5A quasispecies of sequential isolates from 15 treated (nine sustained responders and six non-responders) and three untreated patients were performed. Accumulation of mutations in NS5A during therapy was relatively frequent in the V3 domain, but unusual elsewhere. Amino acid changes were the result of the imposition of minor variants that were already present before treatment and always occurred within the first week of therapy. Before treatment, the complexity and diversity of quasispecies were lower in isolates from responders than in those from non-responders, particularly in the V3 domain, where differences in nucleotide entropy (0·35 vs 0·64, =0·003), genetic distance (0·0145 vs 0·0302, =0·05) and non-synonymous substitutions (0·0102 vs 0·0203, =0·036) were statistically significant. These differences became more apparent during treatment, because complexity and diversity remained stable or tended to increase in non-responders, whereas they tended to decrease in responders. These observations suggest that the composition and dynamics of HCV NS5A quasispecies, particularly in the V3 domain, may play a role in the response to combined IFN/ribavirin therapy.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80526-0
2005-04-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/4/vir861067.html?itemId=/content/journal/jgv/10.1099/vir.0.80526-0&mimeType=html&fmt=ahah

References

  1. Davis G. L., Esteban-Mur R., Rustgi V. 8 other authors 1998; Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493–1499 [CrossRef]
     [Google Scholar]
  2. Domingo E. 1996; Biological significance of viral quasispecies. Viral Hepatitis Rev 2:247–261
     [Google Scholar]
  3. Duverlie G., Khorsi H., Castelain S., Jaillon O., Izopet J., Lunel F., Eb F., Penin F., Wychowski C. 1998; Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 79:1373–1381
     [Google Scholar]
  4. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Izumi N., Marumo F., Sato C. 1995; Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96:224–230 [CrossRef]
     [Google Scholar]
  5. Enomoto N., Sakuma I., Asahina Y. 7 other authors 1996; Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77–81 [CrossRef]
     [Google Scholar]
  6. Farci P., Purcell R. H. 2000; Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 20:103–126
     [Google Scholar]
  7. Felsenstein J. 1993 phylip (phylogeny inference package), version 3.5c Department of Genetics, University of Washington; Seattle, USA:
     [Google Scholar]
  8. Forns X., Bukh J. 1999; The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin Liver Dis 3:693–716 [CrossRef]
     [Google Scholar]
  9. Forns X., Purcell R. H., Bukh J. 1999; Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 7:402–410 [CrossRef]
     [Google Scholar]
  10. Franco S., Giménez-Barcons M., Puig-Basagoiti F., Furčić I., Sánchez-Tapias J.-M., Rodés J., Sáiz J.-C. 2003; Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease. J Med Virol 71:195–204 [CrossRef]
     [Google Scholar]
  11. Gale M. J. Jr, Korth M. J., Tang N. M., Tan S.-L., Hopkins D. A., Dever T. E., Polyak S. J., Gretch D. R., Katze M. G. 1997; Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217–227 [CrossRef]
     [Google Scholar]
  12. Gerotto M., Sullivan D. G., Polyak S. J., Chemello L., Cavalletto L., Pontisso P., Alberti A., Gretch D. R. 1999; Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. J Virol 73:7241–7247
     [Google Scholar]
  13. Giménez-Barcons M., Franco S., Suárez Y. 10 other authors 2001; High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. Hepatology 34:158–167 [CrossRef]
     [Google Scholar]
  14. Inchauspe G., Zebedee S., Lee D.-H., Sugitani M., Nasoff M., Prince A. M. 1991; Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci U S A 88:10292–10296 [CrossRef]
     [Google Scholar]
  15. Kato N., Hijikata M., Ootsuyama Y., Nakagawa M., Ohkoshi S., Sugimura T., Shimotohno K. 1990; Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 87:9524–9528 [CrossRef]
     [Google Scholar]
  16. Kumar S., Tamura K., Nei M. 1994; mega: Molecular Evolutionary Genetics Analysis software for microcomputers. Comput Appl Biosci 10:189–191
     [Google Scholar]
  17. López-Labrador F. X., Ampurdanés S., Forns X. 7 other authors 1997; Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol 27:959–965 [CrossRef]
     [Google Scholar]
  18. Macdonald A., Harris M. 2004; Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85:2485–2502 [CrossRef]
     [Google Scholar]
  19. Martell M., Esteban J. I., Quer J., Genescà J., Weiner A., Esteban R., Guardia J., Gómez J. 1992; Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66:3225–3229
     [Google Scholar]
  20. McHutchison J. G., Gordon S. C., Schiff E. R. 7 other authors 1998; Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492 [CrossRef]
     [Google Scholar]
  21. Meurs E. F., Galabru J., Barber G. N., Katze M. G., Hovanessian A. G. 1993; Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A 90:232–236 [CrossRef]
     [Google Scholar]
  22. Murphy M. D., Rosen H. R., Marousek G. I., Chou S. 2002; Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 47:1195–1205 [CrossRef]
     [Google Scholar]
  23. Nousbaum J.-B., Polyak S. J., Ray S. C., Sullivan D. G., Larson A. M., Carithers R. L. Jr, Gretch D. R. 2000; Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 74:9028–9038 [CrossRef]
     [Google Scholar]
  24. Pawlotsky J.-M., Germanidis G. 1999; The non-structural 5A protein of hepatitis C virus. J Viral Hepat 6:343–356 [CrossRef]
     [Google Scholar]
  25. Pawlotsky J.-M., Germanidis G., Neumann A. U., Pellerin M., Frainais P. O., Dhumeaux D. 1998; Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol 72:2795–2805
     [Google Scholar]
  26. Polyak S. J., McArdle S., Liu S.-L. 8 other authors 1998; Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 72:4288–4296
     [Google Scholar]
  27. Poynard T., Marcellin P., Lee S. S. 8 other authors 1998; Randomised trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426–1432 [CrossRef]
     [Google Scholar]
  28. Puig-Basagoiti F., Sáiz J.-C., Forns X. 7 other authors 2001; Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J Med Virol 65:35–44 [CrossRef]
     [Google Scholar]
  29. Sáiz J. C., Ampurdanés S., Olmedo E. 8 other authors 1997; Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapy. J Hepatol 26:787–793 [CrossRef]
     [Google Scholar]
  30. Sáiz J.-C., López-Labrador F.-X., Ampurdanés S., Dopazo J., Forns X., Sánchez-Tapias J.-M., Rodés J. 1998; The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis 177:839–847 [CrossRef]
     [Google Scholar]
  31. Sánchez-Fueyo A., Giménez-Barcons M., Puig-Basagoiti F., Rimola A., Sánchez-Tapias J. M., Sáiz J. C., Rodés J. 2001; Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. J Med Virol 65:266–275 [CrossRef]
     [Google Scholar]
  32. Soguero C., Campo E., Ribalta T., Sánchez-Tapias J. M., Sáiz J. C., Bruguera M. 2000; Assessment of genotype and molecular evolution of hepatitis C virus in formalin-fixed paraffin-embedded liver tissue from patients with chronic hepatitis C virus infection. Lab Invest 80:851–856 [CrossRef]
     [Google Scholar]
  33. Thompson J. D., Higgins D. G., Gibson T. J. 1994; clustal w: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673–4680 [CrossRef]
     [Google Scholar]
  34. Witherell G. W., Beineke P. 2001; Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 63:8–16 [CrossRef]
     [Google Scholar]
  35. World Health Organization 1997; Hepatitis C: global prevalence. Wkly Epidemiol Rec 72:65–72
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80526-0
Loading
Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C
J. Gen. Virol. 86, 1067 (2005); https://doi.org/10.1099/vir.0.80526-0
/content/journal/jgv/10.1099/vir.0.80526-0
/content/journal/jgv/10.1099/vir.0.80526-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error